Natera, Inc. $NTRA Shares Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its position in shares of Natera, Inc. (NASDAQ:NTRA) by 10.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 66,016 shares of the medical research company’s stock after acquiring an additional 6,208 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Natera were worth $10,627,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. grew its position in Natera by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock worth $2,141,594,000 after purchasing an additional 282,826 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Natera by 44.3% during the second quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock worth $1,795,125,000 after buying an additional 3,263,822 shares during the period. Geode Capital Management LLC grew its holdings in Natera by 7.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock worth $430,640,000 after buying an additional 166,768 shares in the last quarter. Franklin Resources Inc. increased its position in Natera by 20.6% in the 2nd quarter. Franklin Resources Inc. now owns 1,937,647 shares of the medical research company’s stock valued at $327,346,000 after acquiring an additional 330,696 shares during the period. Finally, AQR Capital Management LLC raised its stake in Natera by 44.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,726,750 shares of the medical research company’s stock valued at $291,717,000 after acquiring an additional 532,769 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Performance

Natera stock opened at $231.14 on Friday. The firm has a market cap of $31.97 billion, a price-to-earnings ratio of -100.93 and a beta of 1.62. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36. The firm’s 50 day moving average price is $235.91 and its two-hundred day moving average price is $193.80.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The company had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. During the same period in the prior year, the business earned ($0.26) earnings per share. The business’s revenue was up 34.7% compared to the same quarter last year. As a group, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Buying and Selling

In other Natera news, insider Solomon Moshkevich sold 23,205 shares of Natera stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total transaction of $5,447,141.70. Following the transaction, the insider directly owned 144,992 shares in the company, valued at approximately $34,035,422.08. The trade was a 13.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 160,703 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $199.96, for a total value of $32,134,171.88. Following the completion of the sale, the chief executive officer owned 144,816 shares of the company’s stock, valued at $28,957,407.36. The trade was a 52.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 514,528 shares of company stock valued at $114,975,330. Company insiders own 5.63% of the company’s stock.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced completion of enrollment in the randomized ACES‑EMB heart‑transplant trial — a clinical milestone for the transplant franchise (Prospera) that de‑risks the program’s pathway to clinical readouts and potential uptake. Article Title
• Positive Sentiment: Wall Street coverage remains largely favorable: multiple firms maintain buy/outperform views and several have raised targets (MarketBeat summary shows consensus around a “Moderate Buy” and an average target near $249). This supports upside expectations if results and growth continue.
• Neutral Sentiment: Natera reported preliminary Q4 revenue (details in the alert). Preliminary figures may influence sentiment when the final quarter report and guidance are released; investors should watch the formal Q4 release for confirmation versus consensus. Preliminary Q4 Revenue
• Neutral Sentiment: Institutional ownership remains extremely high (~99.9%), which tends to stabilize the shareholder base but can also concentrate selling/Buying flows when large holders move. (Source: MarketBeat summary.) Institutional Data
• Negative Sentiment: Multiple insider sales by senior executives: CFO Michael Burkes Brophy sold several tranches (totaling 5,064 shares across Jan. 20–29) and CEO Steven Chapman sold several thousand shares (roughly 5,970 shares across Jan. 27–28). These trades total millions of dollars and may create short‑term selling pressure despite insiders retaining large residual stakes. CFO Form 4 CEO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold smaller tranches. While each reduction is under ~1% of those insiders’ holdings, the cluster of sales amplifies negative signaling to the market. Fesko Form 4 Moshkevich Form 4

Analyst Ratings Changes

NTRA has been the topic of a number of research analyst reports. Guggenheim raised their price target on Natera from $230.00 to $270.00 and gave the company a “buy” rating in a report on Monday, January 5th. JPMorgan Chase & Co. boosted their price target on shares of Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Citigroup initiated coverage on shares of Natera in a report on Wednesday, January 7th. They issued a “buy” rating and a $300.00 price objective for the company. Canaccord Genuity Group reissued a “buy” rating on shares of Natera in a report on Monday, January 12th. Finally, UBS Group increased their price target on Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $249.20.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.